このアイテムのアクセス数: 333
このアイテムのファイル:
| ファイル | 記述 | サイズ | フォーマット | |
|---|---|---|---|---|
| s00280-011-1691-z.pdf | 156.69 kB | Adobe PDF | 見る/開く |
| タイトル: | Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation. |
| 著者: | Togashi, Yosuke Masago, Katsuhiro Fukudo, Masahide Tsuchido, Yasuhiro    https://orcid.org/0000-0003-1306-3652 (unconfirmed)Okuda, Chiyuki Kim, Young Hak Ikemi, Yasuaki Sakamori, Yuichi https://orcid.org/0000-0001-6421-7266 (unconfirmed)Mio, Tadashi Katsura, Toshiya Mishima, Michiaki |
| 著者名の別形: | 冨樫, 庸介 |
| キーワード: | Non-small cell lung cancer Epidermal growth factor receptor Tyrosine kinase inhibitor Erlotinib Central nervous system metastasis Cerebrospinal fluid |
| 発行日: | Oct-2011 |
| 出版者: | Springer |
| 誌名: | Cancer chemotherapy and pharmacology |
| 巻: | 68 |
| 号: | 4 |
| 開始ページ: | 1089 |
| 終了ページ: | 1092 |
| 抄録: | Recent reports indicate that refractory central nervous system (CNS) metastases of non-small cell lung cancer (NSCLC) are improved by high-dose gefitinib or erlotinib administration. We describe a Japanese woman with NSCLC and CNS metastases who was resistant to 75 mg daily erlotinib, but the metastases were improved by 150 mg daily erlotinib. We investigated the plasma and CSF concentrations of erlotinib at each dose as well as the correlation between the plasma and CSF concentrations of erlotinib. |
| 著作権等: | The final publication is available at www.springerlink.com この論文は出版社版でありません。引用の際には出版社版をご確認ご利用ください。 This is not the published version. Please cite only the published version. |
| URI: | http://hdl.handle.net/2433/150439 |
| DOI(出版社版): | 10.1007/s00280-011-1691-z |
| PubMed ID: | 21681573 |
| 出現コレクション: | 学術雑誌掲載論文等 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。